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Abstract 
Eating habits, lifestyles, and exposure to specific environmental factors can greatly impact the risk of developing type 
2 diabetes (T2D), influence the genome epigenetically, and affect the expression of genes, including genes related to 
glycemic control, at any stage of life. The epigenetic mechanism underlying obesity and T2D pathogenesis remains 
poorly understood. Conventional strategies for the treatment of obesity and its comorbidities often have poor long‑
term adherence, and pharmacological interventions are limited. Bariatric surgery is the most effective current option 
to treat severe obesity, and Roux‑en‑Y gastric bypass (RYGB) is the most applied technique worldwide. Epigenetic 
changes differ depending on the approach used to treat obesity and its associated comorbidities (clinical or surgical). 
Compared to primary clinical care, bariatric surgery leads to much greater loss of body weight and higher remission 
rates of T2D and metabolic syndrome, with methylation profiles in promoter regions of genes in obese individuals 
becoming similar to those of normal‑weight individuals. Bariatric surgery can influence DNA methylation in parallel 
with changes in gene expression pattern. Changes in clinical biomarkers that reflect improvements in glucose and 
lipid metabolism after RYGB often occur before major weight loss and are coordinated by surgery‑induced changes 
in intestinal hormones. Therefore, the intestine methylation profile would assist in understanding the mechanisms 
involved in improved glycemic control after bariatric surgery. The main objectives in this area for the future are to 
identify epigenetic marks that could be used as early indicators of metabolic risk, and to develop treatments able to 
delay or even reverse these epigenetic changes. Studies that provide the “human epigenetic profile” will be of con‑
siderable value to identify tissue‑specific epigenetic signatures and their role in the development of chronic diseases. 
Further studies should apply methods based on global analysis of the genome to identify methylated sites associated 
with disease and epigenetic marks associated with the remodeling response to bariatric surgery. This review describes 
the main epigenetic alterations associated with obesity and T2D and the potential role of RYGB in remodeling these 
changes.
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Background
Epigenetics concerns mechanisms for modifying gene 
expression at the transcriptional level, by chemical modi-
fications of DNA and RNA chromatin. These modifi-
cations are heritable by meiotic or mitotic processes, 
impact gene function, and cannot be explained by 
changes in the DNA sequence [1]. Environmental fac-
tors may alter phenotypes by modifying gene expression, 
but not gene sequence, leading to epigenetic modifica-
tions [1]. Epigenetics changes include alterations in DNA 
methylation, chromatin, and posttranslational modifica-
tions of histones and micro RNAs. They can deregulate 
up to 6–10% of the genes in some cells and are associated 
with disease pathophysiology [2, 3]. The importance of 
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in the pathogenesis of cancer in 1980 [2]. More recently, 
there have been reports of the relevant roles of DNA 
methylation in obesity and type 2 diabetes (T2D) devel-
opment [2].
In contrast to gene changes, epigenetic modifications 
are reversible. This characteristic may allow for the iden-
tification of novel therapeutics based on functional gene 
restoration. Therefore, an understanding of epigenetic 
mechanisms can be clinically relevant for the treatment 
of some chronic diseases [2, 4]. This review describes the 
compilation of observations from experimental (donated 
organs) and clinical studies published in the databases 
PUBMED, SCIELO, MEDLINE, SCOPUS, WEB OF SCI-
ENCE and LILACS that focused on epigenetic alterations 
associated with obesity and T2D and the potential role 
of Roux-en-Y gastric bypass (RYGB) in remodeling these 
changes, as an effective therapeutic tool for the treatment 
of severe obesity and its associated comorbidities.
Main text
DNA methylation
All of the cells in a given organism’s tissues have identi-
cal DNA. This genetic material contains key informa-
tion to perform any function, although not all genes are 
expressed at once. Moreover, DNA does not determine 
all of the cells’ features. Gene regulation, through epi-
genetic marks in the DNA or cell nucleus proteins, 
allow each cell to acquire its specific function [5]. Envi-
ronmental factors can affect individual phenotypes by 
inducing epigenetic changes, which alter the DNA chro-
matin structure and gene accessibility to transcriptional 
machinery [6].
One of the many epigenetic events to influence gene 
expression, DNA methylation consists of the covalent 
addition of a methyl radical (CH3) to a cytosine base in 
DNA, converting cytosine into 5-methylcytosine (5mC, 
Fig.  1) [7]. This reaction is catalyzed by DNA methyl-
transferases (DNMTs), such as DNMT1, DNMT3A, 
and DNMT3B [8]. DNMT1 is involved in the mainte-
nance of DNA methylation patterns during cell division. 
DNMT3A and DNMT3B are de novo methyltransferases 
that are highly expressed in embryonic stem cells due 
to the elevated rate of de novo methylation at this stage 
[8–11].
Methylation of mammalian genomes occurs almost 
exclusively at cytosine linked to guanine residues through 
phosphodiester bonds at 5′-cytosine-phosphate-guanine 
(CpG) sequences, termed dinucleotides or CpG islands. 
There are approximately 29,000 CpG islands in the 
human genome [6]. CpG islands surround the promoters 
Fig. 1 DNA methylation of mammalian genomes
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of constitutively expressed genes, which are demethyl-
ated [12]. CpG methylation can partially or completely 
prevent expression of the adjacent gene. Therefore, the 
transcription rate of genes containing the 5′-CpG region 
is often inversely proportional to their methylation [12].
The DNA methylation pattern is not uniform among 
eukaryotes or between species [13]. Methylation maps in 
human cell lines reveal that approximately 5% of all cyto-
sine residues are methylated under normal physiological 
conditions [12]. As the primary function of DNA meth-
ylation is to silence active genes in DNA regions, high 
levels of DNA methylation are found in centromeres, 
telomeres, and inactive X chromosomes [14]. However, 
DNA methylation can occur in various locations within 
a gene, including the promoter region, exons, introns, 
and non-translated regions [15]. Non-CpG methylation 
also has been observed in humans [16], predominantly in 
embryonic stem cells [13].
The influence of DNA methylation on gene expression 
appears to depend on where methylation takes place in 
the gene sequence [17]. Methylation in promoter regions 
prevents transcription; methyl groups must be removed 
for reactivation of gene transcription [5]. Although not 
fully understood, gene methylation in intragenic regions 
appears to increase rather than silence gene activity. 
Actively transcribed genes exhibit high methylation lev-
els in intragenic regions that favor mutations and are 
often associated with cancer [18].
A key discovery in epigenetics science was that DNA 
5mC may be oxidized by a family of α-ketoglutarate–
dependent oxygenases known as ten-eleven trans-
location (TET) proteins. These proteins originate 
5-hydroxymethylcytosine (5hmC), 5-formylcytosine 
(5FC), and 5-carboxylcytosine (5caC). Thymine DNA 
glycosylase (TDG) can further process these 5mC deriva-
tives, which are submitted to base excision repair or 
replication-dependent dilution, thereby leading to DNA 
demethylation [9]. The 5mC oxidation products are later 
reversed by unknown decarboxylases or removed by 
TDG and replaced with intact cytosines (Fig. 2) [10, 11]. 
Exact mechanisms by which methyl groups are removed 
and other factors remain unclear.
In short, epigenetic marks, which can be reversible, 
may change the way that gene transcription is controlled 
in the cell. Recent discoveries have increased interest 
in the role of epigenetic changes in the development of 
chronic diseases, as well as in potential therapeutics that 
can reverse these changes [2].
Genetic, environmental factors, and epigenetics
Different forms of genetic variability, particularly sin-
gle nucleotide polymorphisms (SNPs), have been asso-
ciated with the current obesity and T2D epidemic [6]. 
Some polymorphisms alter protein coding in a way that 
impacts a range of T2D-associated pathways (i.e., syn-
thesis, processing, and secretion of insulin; deposition of 
amyloid protein in pancreatic β cells; insulin resistance 
[IR]; and impaired gluconeogenesis regulation) but con-
tributes little to the risk of disease development [6, 20, 
21]. Human epigenotypes can be passed on through gen-
erations and predispose individuals to obesity and T2D 
with much greater power than any single polymorphism 
so far identified [6]. Eating habits, lifestyles, and exposure 
to specific environmental factors are commonly inher-
ited from family. These factors can greatly impact the 
risk of developing T2D, influence the genome epigeneti-
cally, and affect the expression of genes, including genes 
related to glycemic control, at any stage of life [22].
DNA methylation varies among healthy individuals due 
to a combination of genetic and environmental influences 
and stochastic events, such as surgery for weight loss 
[2]. Studies investigating the stability and interindividual 
variations of DNA methylation in peripheral blood have 
compared changes in methylation profiles for relatively 
short (days) and long (years) periods. Some methylation 
marks varied significantly over time, representing mark-
ers influenced by the environment. Other epigenetic 
marks were highly stable, representing values determined 
by genetics [2, 23]. The stability and interindividual vari-
ation of DNA methylation were dependent on genomic 
location. Differentially methylated regions were rich in 
SNPs, suggesting a mechanism by which some SNPs may 
affect gene function [3, 23, 24].
Epigenetics of obesity
Several studies have assessed the relation between site-
specific DNA methylation and obesity. These studies 
focused on potential gene targets for obesity, appetite 
control, and insulin signaling, some of which were 
selected based on previous findings of altered gene 
expression in the same subject. Most of these stud-
ies had a cross-sectional design (e.g., DNA methyla-
tion was measured at the same time point), preventing 
researchers from being able to establish whether DNA 
methylation is a cause or a consequence of the obesity 
phenotype [2].
Low levels of methylation in tumor necrosis factor 
(TNF) and leptin (LEP) genes and high levels of methyla-
tion in proopiomelanocortin (POMC) and aryl hydrocar-
bon receptor nuclear translocator-1 (BMAL1) genes were 
identified in whole blood samples or peripheral blood 
leukocytes of obese subjects [25–28]. Studies demon-
strated associations of body mass index (BMI) or adipos-
ity with methylation of several genes, including pyruvate 
dehydrogenase kinase 4 (PDK4) in skeletal muscle and 
in type 1 receptor for melanin-concentrating hormone 
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(MCHR1), serotonin transporter (SLC6A4), androgen 
receptor (AR), 11-beta-hydroxysteroid dehydrogenase 
type 2 (HSD2) of the period circadian clock 2 (PER2), 
and glucocorticoid receptor (GR) in peripheral blood leu-
kocytes [28–33]. Taken together, these findings support 
the notion that obesity may be associated with epigenetic 
regulation of genes with a central role in intermediary 
metabolism.
The field of epigenetics is relatively new, and its pro-
gress has been hampered by difficulties in acquiring large 
numbers of tissues and homogeneous targets [34]. The 
recent development of next-generation technologies has 
allowed the global assessment of large numbers of genes 
and CpG islands, providing more robust data than the 
usual analysis targeting specific genes [2]. Technological 
advances have enabled the development of large-scale 
studies of the epigenome and its integration with geno-
type, transcriptome, and environment, known as epige-
nome-wide association studies (EWAS).
In a systematic review of 46 studies applying a global 
approach, the authors highlighted a lack of consistent 
evidence to establish a relationship between global DNA 
methylation and obesity [2]. However, the examined 
studies identified multiple methylated loci associated 
with obesity, especially in blood cells [25–28, 30–32, 35, 
36].
Weight loss has been associated with a few changes in 
site-specific DNA methylation, mainly in genes involved 
in weight control, insulin secretion, inflammation, and 
circadian rhythm. Several associations have been made 
between methylation marks at birth and weight in later 
life [2]. The apparent modification of the methylation 
profile by weight loss suggests that some methylation 
marks can be a consequence of the obesity phenotype 
rather than programmed marks that predispose an indi-
vidual to the disease [2]. Comparing the methylation 
profiles of obese individuals with and without success 
in achieving intentional weight loss after dietetic and 
Fig. 2 Mammalian DNA demethylation process (modified from [19]). Cytosine may be methylated by DNMTs and affect gene transcription. In the 
process of demethylation, the methylated product 5mC can be actively reversed by TET proteins and TDG, thereby reverting to the cytosine form. 
Intermediate products include 5hmC, 5FC, and 5caC. Amount of 5hmC reflects DNA demethylation status
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surgical interventions would identify biomarker predic-
tors of individual response to weight loss interventions. 
Potential epigenetic markers for obesity have been iden-
tified, and several of these markers are modifiable by 
changing the exposure in utero or the lifestyle in adult 
life. These findings may allow the development of tar-
geted prevention strategies or interventions in postnatal 
life to modify unfavorable epigenomic profiles [2].
Recently, van Dijk et al. reviewed results obtained from 
larger EWAS and other studies. They found that BMI was 
associated with 37 methylation loci, including regions of 
carnitine palmitoyltransferase 1A (CPT1A), ATP binding 
cassette subfamily G member 1 (ABCG1), and sterol reg-
ulatory element binding transcription factor 1 (SREBF1), 
in blood samples and with hypoxia inducible fator 3 
alpha subunit (HIF3A) gene methylation in whole blood 
and adipose tissue. DNA methylation in lymphocyte 
antigen 86 (LY86) in blood leukocytes differed between 
lean and obese subjects. Methylation in the promoter 
region of proliferator-activated receptor G coactivator 1A 
(PGC1A) in the whole blood of children was associated 
with adiposity 5  years later. Methylation of adrenocep-
tor beta 3 (ADRB3) in whole blood was associated with 
waist–hip ratio. BMI and anthropometric measurements 
were associated with methylation in several DNA regions 
of adipose tissue. The authors suggested that methylation 
changes in PGC1A, HIF3A, ABCG1, and CPT1A emerge 
as biomarkers associated with metabolic health and dis-
ease [37]. In fact, EWAS have demonstrated associations 
between methylation of DNA regions and plasma con-
centrations of lipids, serum concentrations of metabo-
lites, IR, and T2D [37].
Epigenetics of T2D
Preventive and therapeutic management of T2D involves 
genetic screening [34]. Individuals who have siblings with 
T2D present 2–3 times higher risk of developing the dis-
ease compared to the general population [38]. For sub-
jects who have one or both parents with T2D, the risk of 
developing the disease increases 30–40 or 70%, respec-
tively [39]. A genome-wide association study (GWAS) 
identified at least 75 independent loci for T2D [34, 40]. 
However, genetic loci explain only a small proportion of 
the risk for T2D. The explosive increase in T2D preva-
lence in recent decades cannot be explained only by 
genetics, as it is unlikely that genomes changed during 
this relatively short period of time [34].
Some evidence suggests that DNA methylation may 
be an intermediate stage in T2D pathogenesis. When 
testing DNA methylation patterns as a potential con-
tributor to variation in T2D risk across the genome, 
Hidalgo et al. identified a significant association of CpG 
methylation in two sites of the ABCG1 gene with insulin 
levels and IR in CD4(+) T cells from normal subjects 
[41]. An association of CpG methylation in the thiore-
doxin-interacting protein (TXNIP) gene with T2D was 
recently observed. TXNIP is involved in glucose uptake 
by skeletal muscles and glucotoxicity-induced pancre-
atic β-cell apoptosis [34]. In addition to TXNIP, CpG 
loci of ABCG1, phosphoethanolamine/phosphocho-
line phosphatase (PHOSPHO1), suppressor of cytokine 
signaling 3 (SOCS3) and SREBF1 genes in peripheral 
blood were significantly associated with development of 
T2D [42]. Dayeh et al. assessed methylation in approxi-
mately 1649 CpG regions of 853 genes in pancreatic 
islet cells from 15 patients with T2D and 34 nondia-
betic controls. They observed altered methylation pro-
files in all studied genes, including transcription factor 
7 like 2 (TCF7L2), fat mass and obesity-associated pro-
tein (FTO), and kidney and cardiac voltage dependend 
K+  channel [KCNQ1], as well as altered methylation 
and gene expression levels for 102 genes, including cyc-
lin dependent kinase inhibitor 1A (CDKN1A), phospho-
diesterase 7B (PDE7B), septin 9 (SEPT9), and exocyst 
complex component 3 like 2 (EXOC3L2). Importantly, 
methylation of these genes can affect pancreatic cell 
function [43].
The epigenetic mechanism underlying T2D pathogen-
esis remains poorly understood, although it is well estab-
lished that environmental factors play a central role in 
T2D development and may modulate gene expression by 
epigenetic mechanisms [34]. Environmental factors can 
include the inadequate lifestyle associated with obesity 
pathogenesis, which has T2D as a commonly associated 
comorbidity. T2D is accompanied by altered metabo-
lisms of methyl-, folic acid-, homocysteine-, and cho-
line-donator cells. Homocysteine metabolism imbalance 
is an important biomarker for various diseases and can 
alter methyl group metabolism and epigenetic methyla-
tion control. Clinical studies associated hyperhomocyst-
einemia in diabetes with renal dysfunction and impaired 
ability to catabolize homocysteine as a result of disease 
progression [44]. T2D-induced changes in methyl group 
metabolism suggest that DNA methylation may be com-
promised, favoring hypomethylation.
DNA hypomethylation has been observed in T2D sub-
jects. A large EWAS assessed the epigenome of periph-
eral blood from subjects (n  =  1169) with T2D and 
control individuals [45]. Compared to controls, T2D sub-
jects presented a greater number of differentially methyl-
ated sites in genomic loci previously associated with T2D 
in a GWAS [41]. Hypomethylation of CpG islands in the 
FTO gene (3.35%) was significantly associated with T2D 
risk. The authors suggested that the relationship between 
methylation and gene expression should be studied in 
tissues associated with T2D pathophysiology because 
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FTO is expressed in many of these tissues (i.e., pancreatic 
islands, skeletal muscle, and adipose) [45].
Data from tissue methylation can provide new insights 
into the epigenetics of T2D. For instance, hypometh-
ylation of genes from liver tissue seem to contribute to 
T2D pathogenesis. When comparing epigenetic changes 
of liver DNA in obese patients with (n =  35) and with-
out (n = 60) T2D, Nilsson et al. found an association of 
T2D with 251 CpG regions with altered DNA methyla-
tion. These regions included CpG regions of T2D-related 
genes, such as growth factor receptor bound protein 
10 (GRB10), ATP binding cassette subfamily C mem-
ber 3 (ABCC3), monoacylglycerol O-acyltransferase 1 
(MOGAT1), and PR domain 16 (PRDM16), approxi-
mately 94% of which were hypomethylated. Another 29 
hepatic genes with altered methylation in T2D patients 
presented altered expression [46].
Kirchner et  al. [47] evaluated global gene methylation 
and expression in hepatic tissues from severely obese 
men with or without T2D and from a nonobese control 
group. Severe obesity was associated with hypometh-
ylation of genes involved in hepatic glucose metabolism 
and IR, in parallel with increased levels of gene expres-
sion. Binding sites for activating transcription factor 
(ATF) motifs were found in several of the genes, includ-
ing glucokinase (GCK) and phosphofructokinase, liver 
type (PFKL), involved in liver glycolysis, acetyl-CoA car-
boxylase alpha (ACACA), ATP citrate lyase (ACLY), fatty 
acid synthase (FASN), involved in de novo lipogenesis, 
and protein kinase C epsilon (PRKCE), involved in insu-
lin signaling. Hypomethylation of CpG sites within ATF 
motifs in these genes was highlighted by a genome-wide 
DNA methylation assay of liver samples from severely 
obese patients with and without T2D, compared to non-
obese controls. However, the DNA methylation pat-
tern at these ATF motifs inversely mirrored the mRNA 
expression levels when comparing patients with and 
without T2D, except for ACLY. In addition, mRNA and 
protein expression levels of PRKCE were increased only 
in nondiabetic obese patients. The authors concluded 
that severe obesity is accompanied by changes in the 
methylation profiles of several genes controlling glucose 
metabolism within the ATF motif regulatory site. These 
changes are associated with PRKCE activation and hypo-
methylation and seem to favor liver glycolysis and lipo-
genesis, contributing to IR (Fig. 3).
In summary, acquired data support the association of 
epigenotypes with obesity and T2D risk. This informa-
tion may aid in the identification of epigenetic mark-
ers with potential predictive value for early diagnosis of 
these diseases [6]. For instance, the predictive power of 
FTO methylation for T2D was independent of any known 
polymorphism and significantly higher than any genetic 
variant described to date. Other methylation markers 
of obesity and T2D, summarized in Table 1, may repre-
sent early markers for risk of obesity and T2D and the 
response to lifestyle, pharmacological, or surgical inter-
ventions [6].
Epigenetic response to bariatric surgery
Conventional strategies for the treatment of obesity and 
its comorbidities (i.e., lifestyle changes) often have poor 
long-term adherence, and pharmacological interventions 
are limited [29]. Bariatric surgery is the most effective 
current option to treat severe obesity, and RYGB is the 
most applied technique worldwide. Considered a “meta-
bolic surgery”, RYGB increases insulin sensibility even 
before substantial weight loss is achieved, contributing to 
clinical improvement or remission of T2D.
Although early alterations in intestinal hormone (i.e., 
incretin) release have been suggested as a potential factor 
involved in post-RYGB glucose homeostasis, the molec-
ular mechanisms associated with these alterations are 
poorly understood [29]. Similarly to physical activity and 
dietetic interventions, bariatric surgery can change DNA 
methylation patterns in different biological samples [2]. 
However, the epigenetic changes differ depending on the 
approach used to treat obesity and its associated comor-
bidities (clinical or surgical).
Nicoletti et  al. studied whether induced weight loss 
can affect global DNA methylation of long interspersed 
nuclear elements (e.g., LINE-1) or the methylation and 
hydroxymethylation profiles (as markers of increased 
gene expression) of inflammatory genes in obese patients. 
Their study focused on 22 obese patients who underwent 
caloric restriction based on a Mediterranean diet, 14 
obese patients who underwent bariatric surgery, and 9 
nonobese controls. DNA methylation patterns depended 
on the applied obesity treatment. LINE-1 methylation 
levels did not change after weight loss, regardless of treat-
ment, whereas interleukin 6 (IL6) methylation increased 
after energy restriction and decreased after bariatric sur-
gery [48].
Another study considered the methylation profiles of 
promoters of several genes (PPARG coactivator 1 alpha 
[PPARGC1A], PDK4, transcription factor A, mitochon-
drial [TFAM], interleukin 1 beta [IL1B], IL6, and TNF) 
in blood from obese and nonobese patients. This study 
included severely obese nondiabetic patients who were 
on a very low calorie diet (VLCD) for 14 days (n = 18), 
followed in some cases by RYGB (n = 7), and nonobese 
control patients who underwent elective cholecystectomy 
(n =  6) [49]. Decreased methylation in the promoter of 
PPARGC1A was observed after VLDC. Significantly 
decreased levels of methylation were observed in the pro-
moters of PPARGC1A, IL1B, IL6, and TNF 2  days after 
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RYGB. However, significantly increased methylation lev-
els were observed in the promoters of PDK4, IL1B, IL6, 
and TNF 12 months after RYGB. These data suggest that 
epigenetic changes after intervention for obesity differ 
according to the intervention type. Compared to clinical 
approaches, epigenetic changes seem to be more relevant 
after bariatric surgery and potentially contribute to post-
operative metabolic homeostasis [49].
Compared to primary clinical care, bariatric surgery 
leads to much greater loss of body weight and higher 
remission rates of T2D and metabolic syndrome [50], 
with methylation profiles in promoter regions of genes 
in obese individuals becoming similar to those of nor-
mal-weight individuals [2]. Barres et al. compared DNA 
methylation and gene expression levels in skeletal mus-
cle of nonobese control women (n = 9) to levels in obese 
women (n = 8) before and 6 months after RYGB. Obesity 
was associated with changes in expression levels of genes 
related to mitochondrial function. After bariatric surgery, 
expression levels of 11 of the 14 studied genes were simi-
lar to those of nonobese control patients. Methylation of 
promoter regions of PGC1A and PDK4 were altered in 
obese women, but normalized after RYGB to the levels 
in control women [29]. Normalization of gene expression 
and methylation occurred in parallel with normaliza-
tion of the fasting glucose, insulin, total cholesterol, low-
density lipoprotein, triglyceride, and nonesterified fatty 
acid levels after RYGB surgery. The authors observed an 
opposite pattern between DNA methylation and mRNA 
expression of PGC1A, suggesting that DNA methylation 
is involved in mRNA expression [50].
Methylation of a single cytosine residue in the PGC1A 
promoter induced a marked reduction in gene activ-
ity [51]. Obesity was associated with hypermethylation 
of CpG and exonic regions near transcription initiation 
sites, as well as methylation of a single cytosine resi-
due into a non-CpG site in the PDK4 promoter, which 
decreased gene activity. These findings suggest that 
altered DNA methylation, even in non-CpG regions, is 
involved in the physiological control of gene transcrip-
tion in obese women. RYGB can normalize these altered 
methylation patterns in parallel with improvements in 
clinical variables associated with insulin sensitivity after 
weight loss [29].
Fig. 3 Proposed hypothesis of epigenetic mechanisms in liver contributing to IR in severe obesity, based on findings from Kirchner et al. [47]. 
Increased hepatic glycolysis and de novo lipogenesis are associated with DNA hypomethylation within ATF motifs of genes involved in glycolysis 
and IR. An excess of pyruvate from glycolysis is not used for ATP synthesis in the tricarboxylic acid (TCA) cycle and is converted to fatty free acids 
(FFA), which activate transcription of CƐ kinase that remains silenced by hypomethylation, increasing CE kinase (PRKCE) levels. The action and 
increased levels of PRKCE have been implicated in decreased insulin signaling. Therefore, the liver of severely obese patients is programmed to 
become insulin‑resistant, possibly contributing to T2D and nonalcoholic fatty liver disease (NAFLD). Continuous arrows represent activation of stud‑
ied glycolysis and lipogenesis pathways. Discontinuous arrows represent the proposed hypothesis
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In another study, the response of DNA methylation in 
promoter regions to RYGB was assessed in whole blood 
from obese patients before and 6  months after RYGB 
(n = 11) and nonobese controls (n = 16), in parallel with 
fasting glucose levels. RYGB was associated with changes 
in DNA methylation in 51 promoters (28 positively and 23 
negatively regulated), with enrichment for genes involved 
in metabolic processes. In contrast to data before surgery, 
the mean DNA methylation level in all of these promoters 
after RYGB was similar to that found in the control group. 
When the authors controlled for weight loss (−24%) and 
fasting glucose (−16%) after RYGB, only the promoter for 
adenosine kinase (ADK) presented with DNA methyla-
tion significantly different from preoperative values (10% 
lower than basal). Adenosine can improve insulin secre-
tion, decrease glucose production, and stimulate glucagon 
secretion [52]. These data suggest that changes in DNA 
methylation after RYGB may contribute to the observed 
improvement in glucose metabolism. These data also sup-
port an important role for epigenetic changes in develop-
ment and predisposition to metabolic diseases, such as 
obesity and T2D [52].
Epigenetic changes in genes involved in obesity and glu-
cose homeostasis experienced by obese women after bari-
atric surgery may be inherited by their descendants [53]. A 
recent retrospective study examined DNA methylation pat-
terns in the blood of brothers born before (n =  531) and 
after (n  =  531) maternal bariatric surgery. Siblings born 
before versus after bariatric surgery showed different meth-
ylation patterns in 3074 genes involved in insulin receptor 
signaling, T2D, leptin signaling, and obesity [53].
Organ-specific epigenetic signatures after bariatric 
surgery have been identified in organs involved in obe-
sity and T2D pathogenesis. Ahrens et  al. obtained liver 
biopsies from 63 patients, classified histologically as 
normal controls (n  =  18) and nonalcoholic fatty liver 
disease (NAFLD) patients distributed into healthy obese 
(n = 18), steatosis (n = 12), and nonalcoholic steatohep-
atitis (NASH, n =  15) phenotypes [54]. Altered expres-
sion and methylation patterns of nine genes encoding 
key enzymes involved in intermediary metabolism (e.g., 
pyruvate carboxylase [PC], ACLY, and phospholipase C 
gamma 1 [PLCG1]) and insulin signaling (e.g., insulin like 
growth factor 1 [IGF1], insulin like growth factor bind-
ing protein 2 [IGFBP2], and PRKCE) were associated 
with NAFLD. When the analysis was replicated in 39 
independent liver samples from NAFLD obese patients, 
high transcription levels in CpG regions of zinc finger 
protein 274 (ZNF274), PGC1A, and sterol regulatory 
element binding transcription factor 2 (SREBP2) were 
associated with liver disease [54]. Some of these obese 
patients (n =  23) underwent bariatric surgery and were 
reevaluated 5–9 months after this procedure. Despite the 
expected improvement of liver histology, the intraindi-
vidual comparison of liver biopsies before and after bari-
atric surgery highlighted methylation changes associated 
with liver disease, which appeared to be partially revers-
ible by the surgery. An inverse correlation of the NASH 
phenotype and bariatric surgery was observed, indicating 
that methylation changes associated with NASH can be 
reversed after surgery. Specific methylation signatures 
of NAFLD-related genes (i.e., nuclear respiratory factor 
1 [NRF1], heat shock transcription factor 1  [HSF1], and 
estrogen related receptor alpha [ESRRA]) were clearly 
distinct after the bariatric procedure, both in gene ontol-
ogy and transcription factor binding site analyses. The 
receptor protein tyrosine phosphatase epsilon (PTPRE)-
encoding gene exhibited altered expression and methyla-
tion patterns before and after surgery. Hypermethylation 
and low expression of PTPRE are negative regulators 
of insulin signaling in skeletal muscle, suggesting that 
changes in its expression and methylation after bariatric 
surgery may be involved in the hepatic insulin sensitivity 
restoration observed after the procedure [54].
Adipose tissue plays a key role in the metabolic disor-
der related to obesity. Another study on organ-specific 
epigenetic signatures after bariatric surgery assessed 
DNA methylation profiles in 15 obese women before and 
a mean of 17.5  months after RYGB, when patients had 
achieved up to 27% of body weight loss [55]. After RYGB, 
significant differences in obesity-related gene methylation 
levels were found in subcutaneous and omental adipose 
tissues. Most CpG islands were hypermethylated before 
weight loss. Changes in methylation levels of genes, 
including histone deacetylase 4 (HDAC4), solute car-
rier family 37 member 3 (SLC37A3), and DENN domain 
containing 1 (DENND1C), also known as FAM31C, in 
subcutaneous adipose tissue, correlated with fasting gly-
cemia levels. Significantly different mRNA levels of all 
studied genes presenting with methylation in their pro-
moter regions were found when comparing before and 
after RYGB. These findings suggest that altered DNA 
methylation of adipose tissue may have a role in obesity 
development and can be changed by RYGB, potentially 
contributing to glucose homeostasis [55].
Despite the benefits associated with metabolic and 
weight loss responses to bariatric surgeries, patients 
who undergo these procedures still exhibit a higher risk 
of chronic diseases (including T2D relapse) and mortal-
ity compared to the general population [56]. Postobese 
patients have fat cells that are smaller in size and greater 
in number compared to never-obese subjects [57]. Such 
metabolic disturbances of the fat cells may contribute to 
postoperative complications [58].
A clinical study tested the hypothesis that differen-
tially methylated DNA sites are associated with adipose 
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tissue hyperplasia after bariatric surgery-induced weight 
loss. Genome-wide DNA methylation was analyzed 
in abdominal subcutaneous fat cells collected from 16 
women 2 years after gastric bypass surgery with signifi-
cant weight loss (BMI 26 ± 2 kg/m2) and from 14 never-
obese women (BMI 25 ± 2 kg/m2), both presenting stable 
weight for the previous 6 months. Gene expression was 
assessed in the adipose tissues of 9 women from each 
group. Compared to the never-obese group, the bariatric 
surgery group showed significant global DNA hypometh-
ylation and a greater number of differentially methylated 
sites in adipogenesis genes. In a secondary analysis, the 
authors assessed DNA methylation and expression of 
adipogenesis genes in 15 and 11 obese women, respec-
tively. Differential methylation of adipogenesis genes 
was accompanied by altered expression levels in obese 
but not postobese women. The authors concluded that 
altered methylation of adipogenesis genes in fat cells can 
contribute to adipose tissue hyperplasia in women after 
bariatric surgery [56].
Data obtained until now support a remodeling response 
of altered gene methylation to bariatric surgery, with 
potential effects favoring metabolic homeostasis. These 
effects may include remission of T2D as a comorbidity 
of obesity. Table  1 summarizes the main studies involv-
ing DNA methylation in obesity, T2D, and RYGB. Other 
clinical benefits associated with bariatric surgery seem 
to involve epigenetic changes. Twenty-four promoters 
associated with CpG loci were correlated with changes in 
blood pressure after RYGB. Two of these promoters were 
significantly hypomethylated depending on the presence 
of hypertension [59]. Nevertheless, interventional bariat-
ric surgeries are not free of complications that may also 
involve epigenetic changes.
Current findings are aiding in the identification of epi-
genetic markers with potential predictive value for clini-
cal responses induced by the surgical procedure [6]. For 
instance, baseline methylation levels of serpin family E 
member 1 (SERPINE-1) were significantly lower in obese 
patients presenting relevant weight loss after bariatric 
surgery. Mechanisms dependent on the inhibitor of plas-
minogen activator (PAI-1) encoded by SERPINE-1 are 
involved in the pathogenesis of obesity, IR, and T2D [60], 
and methylation levels of SERPINE-1 have been associ-
ated with obesity and metabolic syndrome [48]. There-
fore, SERPINE-1 gene methylation may be a predictive 
marker of weight loss response to RYGB [48].
Final considerations and conclusions
Thanks to advances in next-generation technologies, 
the field of epigenetics is growing quickly. Not long 
ago, researchers believed that DNA methylation repre-
sented only a gene-silencing mark, and that its increase 
in promoter regions was associated with decreased gene 
expression. Recent studies suggest that DNA methylation 
also affects noncoding RNA expression, transcriptional 
elongation, splicing events, and overall genomic stabil-
ity, depending on the genomic location in CpG regions 
where methylation occurs [46]. Some of these epigenetic 
changes have been associated with the development of 
obesity and T2D. DNA methylation analysis of the entire 
genome is opening a new window for identifying pheno-
types and epigenetic signatures of these clinical condi-
tions [2]. Several methods are commercially available to 
assess global DNA methylation, with the Illumina Infin-
ium Human Methylation 450 BeadChip® emerging as the 
most widely used platform for this purpose. This method 
analyzes more than 450,000 methylation regions in CpG 
sites and other nearby regions, providing reproducible 
quantitative data that could facilitate comparisons across 
studies [2].
Epigenetic researchers in the areas of obesity and T2D 
seek to identify biomarkers that can predict the risk of 
developing these diseases and their associated complica-
tions. They aim to understand the environmental factors 
related to obesity, which can modulate gene expression 
by affecting epigenetic mechanisms. Such understand-
ings would allow the design of new therapeutic strategies. 
However, the characterization of all of the factors able to 
modify epigenetic signatures and their true importance 
for obesity and T2D are affected by the small and cumu-
lative magnitude of changes produced by dietary and 
environmental factors, which differ largely between bio-
logical samples [44].
Peripheral blood is the DNA source most applied in 
epigenetic studies because of the ease of analysis [2]. 
However, blood contains a mixture of cell types with 
different methylation profiles, such that its use in epige-
netic studies may not necessarily reflect the epigenetic 
status of other tissues. Studies that provide the “human 
epigenetic profile” will be of considerable value to iden-
tify tissue-specific epigenetic signatures and their role 
in the development of chronic diseases [2]. In humans, 
the analysis of epigenetic profiles showed significant dif-
ferences between normal weight and obese individuals, 
and between T2D individuals and nondiabetic controls 
[6]. These differences were mainly observed in periph-
eral blood, but also in other types of cells (i.e., pancreatic 
islets) and tissues (i.e., muscle, liver and adipose tissue). 
These and additional findings may help in elucidating 
why obesity and T2D develop in some individuals but not 
others.
Recent findings suggest that epigenetic changes in spe-
cific tissues of patients with T2D are at least partially co-
regulated by variations in DNA sequence. Body weight 
reduction can have a dynamic effect on the epigenome. 
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Considering the role of obesity in T2D development, 
the epigenome is an innovative target for pharmacologi-
cal and environmental therapeutic interventions [6]. The 
identification of predictive epigenetic biomarkers for 
obesity and remodeling markers induced by bariatric sur-
gery may be useful to achieve this aim.
Potential biomarkers for obesity can be detected early, 
enabling prediction of disease risk at a young age, before 
the phenotype develops. This observation opens the 
promising possibility to design intervention strategies for 
the prevention of obesity and, consequently, T2D. Bari-
atric surgery can influence DNA methylation in parallel 
with changes in gene expression pattern. Weight loss that 
can be achieved by these procedures is associated with 
changes in the methylation of CpG sites and between 
exon regions near the transcription sites. Dynamic 
changes in DNA methylation might be an early event that 
drives the transcription of genes involved in the orches-
tral regulation of insulin sensitivity in human obesity 
[29].
Epigenetic regulation seems to be tissue specific; there-
fore, it is important to investigate a homogeneous cell 
type or tissue from a target organ for development of the 
studied disease. The pancreatic islet is one of the most 
thoroughly investigated cell types, and the liver, muscle, 
and adipose tissues are the main investigated tissues for 
T2D. Changes in clinical biomarkers that reflect improve-
ments in glucose and lipid metabolism after RYGB often 
occur before major weight loss and are coordinated by 
surgery-induced changes in intestinal hormones. There-
fore, the intestine has been the subject of major stud-
ies on T2D and bariatric surgery [65, 66]. The intestinal 
methylation profile would assist in understanding the 
mechanisms involved in improved glycemic control after 
bariatric surgery. To complement studies with tissue-
specific approaches to assess the epigenetics of T2D, we 
are currently exploring the effects of bariatric surgery on 
the gastrointestinal methylation profile of obese patients 
with T2D, as part of the SURMetaGIT study (SURgically 
induced Metabolic effects on the Human GastroIntesti-
nal Tract) [67].
In conclusion, evidence supports a potential role of 
epigenetic changes in obesity and T2D pathogenesis. Epi-
genetic profiles seem to be altered by bariatric surgeries 
towards metabolic homeostasis. The main objectives in 
this area for the future are to identify epigenetic marks 
that could be used as early indicators of metabolic risk, 
and to develop treatments able to delay or even reverse 
these epigenetic changes. Further studies should apply 
methods based on global analysis of the genome (pref-
erentially in disease-target tissues) to identify methyl-
ated sites associated with disease and epigenetic marks 
associated with the remodeling response to bariatric 
surgery.
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